Cost Utility of Switching From Trivalent to Quadrivalent Influenza Vaccine in Turkey.

Creative Commons License

Amiche A., Tanriover M., Bellier L., Ugur B., Akin L.

Value in health regional issues, cilt.25, ss.15-22, 2021 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 25
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1016/j.vhri.2020.11.006
  • Dergi Adı: Value in health regional issues
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, ASSIA, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.15-22
  • Anahtar Kelimeler: cost, cost utility, economic analysis, incremental cost-effectiveness ratio, influenza, influenza B virus, public health impact, seasonal influenza, Turkey, vaccination, vaccine, PUBLIC-HEALTH IMPACT, SEASONAL INFLUENZA, SURVEILLANCE, PRODUCTIVITY, STATES
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Objectives: Trivalent influenza vaccines (TIVs) are widely used but protect against only 1 of the 2 co-circulating influenza B virus lineages. Quadrivalent influenza vaccines (QIVs) include a B strain from each lineage to overcome mismatches. The main objective of this study was to determine the cost-utility and budget impact of switching from vaccination with TIV to QIV in the population recommended for influenza vaccination in Turkey.